On Thursday, BioTime BTX will release its latest earnings report. Decipher the announcement with Benzinga's help.
Earnings and Revenue
BioTime EPS is expected to be at a loss of 7 cents, according to sell-side analysts. Sales will likely be near $940,000.
BioTime EPS in the same period a year ago came in at a loss of 5 cents. Sales were $1.08 million. Sales would have fallen 13.20 percent from the same quarter last year.
BioTime's reported EPS has stacked up against analyst estimates in the past like this:
Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
EPS Estimate | -0.08 | -0.09 | -0.14 | |
EPS Actual | -0.08 | -0.11 | -0.08 | -0.05 |
Stock Performance
Over the last 52-week period, shares are down 7.97 percent. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. Analysts generally rate BioTime stock as Neutral. The strength of this rating has dwindled over the past three months.
Conference Call
BioTime's Q4 conference call can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.